Satellos Bioscience (NASDAQ:MSLE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Satellos Bioscience (NASDAQ:MSLE) released its quarterly earnings results on Friday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02), Zacks reports.

Satellos Bioscience Stock Down 2.2%

Shares of MSLE stock traded down $0.16 during mid-day trading on Friday, reaching $7.01. 43,311 shares of the company were exchanged, compared to its average volume of 38,248. The company has a 50 day moving average price of $7.52. The company has a market capitalization of $146.02 million, a P/E ratio of -4.38 and a beta of 1.60. Satellos Bioscience has a fifty-two week low of $4.53 and a fifty-two week high of $13.39.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MSLE shares. Leerink Partners assumed coverage on shares of Satellos Bioscience in a research note on Monday, April 6th. They set an “outperform” rating and a $20.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th. Wall Street Zen raised shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday. Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Finally, Guggenheim assumed coverage on shares of Satellos Bioscience in a research report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.